At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Nilotinib (Tasigna)drug
Likely dose
Nilotinib (Tasigna) 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis
In Brief
A Phase 2 clinical trial evaluating Nilotinib (Tasigna) for Systemic Sclerosis. Completed, enrolled 10 participants across 1 site.
Detailed Summary
A phase IIa open-label single center pilot study to assess the safety and efficacy of Nilotinib in patients with Scleroderma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Sclerosis
CountriesUnited States
CollaboratorsRudolph Rupert Scleroderma Program, Novartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedJul 2010
Primary CompletionJul 2014
Study CompletionJan 2015
TodayJul 2026
First PostedJul 20, 2010
Enrollment StartJul 1, 2010
Primary CompletionJul 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.0 years ago
Interventions
Nilotinib (Tasigna)drug
Patients will be treated with Nilotinib 400 mg two times a day for 6 months.